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Abstract
Background: Lianhuaqingwen Capsule (LH-C) is a traditional Chinese medicine (TCM) formula used to treat respiratory
tract infectious diseases in Chinese. The aim of this study was to determine the antiviral activity of LH-C and its
immunomodulatory effects on viral infection.
Method: The in vitro cytotoxicity and antiviral activity of LH-C was determined by MTT and Plaque reduction assays. Time
course study under single-cycle virus growth conditions were used to determine which stage of viral replication was
blocked. The effect of LH-C on the nuclear export of the viral nucleoprotein was examined using an indirect
immunofluorescence assay. The regulation to different signaling transduction events and cytokine/chemokine
expression of LH-C was evaluated using Western blotting and real-time RT-PCR. After virus inoculation, BALB/c mice were
administered with LH-C of different concentrations for 5 days. Body-weight, viral titers and lung pathology of the mice
were measured, the level of inflammatory cytokines were also examined using real-time RT-PCR.
Results: LH-C inhibited the proliferation of influenza viruses of various strain in vitro, with the 50% inhibitory concentration
(IC50) ranging from 0.35 to 2 mg/mL. LH-C blocked the early stages (0–2 h) of virus infection, it also suppressed virus-
induced NF-kB activation and alleviated virus-induced gene expression of IL-6, IL-8, TNF-a, IP-10, and MCP-1 in
a dose-dependent manner. LH-C treatment efficiently impaired the nuclear export of the viral RNP. A decrease of the
viral titers in the lungs of mice were observed in groups administered with LH-C. The level of inflammatory cytokines
were also decreased in the early stages of infection.
Conclusions: LH-C, as a TCM prescription, exerts broad-spectrum effects on a series of influenza viruses, including the
newly emerged H7N9, and particularly regulates the immune response of virus infection. Thus, LH-C might be a promising
option for treating influenza virus infection.
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Background
Influenza virus, as a common respiratory pathogen,
causes seasonal epidemics and occasional severe
worldwide pandemics. The most recent event including
the 2009 H1N1 pandemic (“swine flu”), and the 2013
H7N9 virus outbreak in China, which led to significant
morbidity and mortality [1, 2].
Human influenza virus infections primarily affect the
upper respiratory tract, resulting in clinical symptoms,
including cough, fever, sore throat, rhinorrhea and
congestion, occasionally followed by lower respiratory
diseases like pneumonia [3, 4]. It has been reported that
pneumonia causes approximately 80% mortality via
influenza virus infection [5]. Upon pathogen infection of
the respiratory tract, the host immune system is acti-
vated to resist and clear the infection. Airway epithelium
cells and alveolar macrophages release multiple pro-in-
flammatory cytokines and chemokines, such as tumor
necrosis factor (TNF-α), interleukin-6 (IL-6), interferon
(IFN), and other chemokines, including IL-8, monocyte
chemoattractant protein-1 (MCP-1), and macrophage in-
flammatory protein (MIP). This release results in the at-
traction and activation of additional inflammatory cells,
including macrophages and neutrophils, into the lungs,
initiating the innate immune system that is crucial for the
clearance and resolution of viral particles [6, 7]. Factors
implicated in severe influenza include robust cytokine
production, otherwise known as the “Cytokine storm”.
This effect has been considered one of the major contrib-
utors to the lethal disease caused by the 1918 pandemic
strain and H5N1 viruses [8, 9].
Under physiological conditions, anti-inflammatory
cytokines regulate the response of inflammation and
attainment of equilibrium. However, the double-sided
functions of cytokines could either be beneficial or detri-
mental to hosts. Under pathological conditions in which
the balance is disrupted, pro-inflammatory responses may
spiral out of control and excessive pro-inflammatory
cytokines and inflammatory immune cells may contribute
to additional tissue damage and inflammation [10, 11].
Vaccination is the most effective way to prevent influenza
infection now. However, the high genetic variability of the
virus renders the protection incomplete. In cases of a newly
emerging strain, vaccination is only available a few months
after the first appearance, leaving the population vulnerable
during the crucial early phases of the pandemic [4].
Currently, two classes of antivirals are used as anti-
influenza drugs: amantadine derivatives that blocking the
virus-specific M2-ion channel and two neuraminidase (NA)
inhibitors: oseltamivir (Tamiflu) and zanamivir (Relenza),
both of which are approved by the FDA [12, 13]. Laninamivir
was approved for the treatment of influenza in Japan in
2010. These drugs interfere with the activity of viral neur-
aminidase. In addition, the nucleoside analogues
ribavirin and favipiravir (T-705) exhibit a suppressive
effect against almost all RNA based human viruses
[13]. However, resistant viruses against these prophy-
lactic agents have emerged in recent years. Amanta-
dine resistance has been detected in human and avian
H5N1 strains, and an increasing number of clinical
strains have been confirmed as resistant NA inhibi-
tors, including oseltamivir and zanamivir [12, 14].
Additionally, all of these therapies are aimed at inhibiting
virus propagation and spread; thus, the inflammation
resulting from infection and the disease remain untreated.
Because the severe outcome of influenza virus infection is
associated with the aberrant production of inflammatory
cytokines, maintaining the immune system in an appropri-
ately robust condition may be detrimental for the preven-
tion of the severe symptoms of influenza [15, 16].
LH-C composed of 13 herbs was extended from two
TCM prescriptions: Maxing Shigan Tang and Yinqiao
San. Maxing Shigan Tang was originally described in a
classical Chinese book Shanghan Lun of Han Dynasty
for the treatments of febrile diseases, it has been
prescribed in treating bronchitis, pneumonia and early
stage of measles [17]. Yinqiao San from the TCM mono-
graph Wenbing Tiaobian of Qing Dynasty was mainly
used for the treatment of “Warm disease” characterized
by fever, thirst and headache. LH-C has been used in
treating regular seasonal influenza for decades. Recently,
A randomized controlled trial for the comparison of
LH-C with oseltamivir in therapeutic effects on patients
with mild H1N1 infection demonstrated that LH-C has
a significant effect on the alleviation of fever, cough, sore
throat and fatigue, it also showed comparative thera-
peutic effectiveness in reduction of illness duration and
viral shedding duration [18, 19].
In the present study, we attempted to elucidate the
mechanisms of LH-C anti-influenza activity, we exam-
ined the effect of LH-C on different influenza virus
strains, and further addressed the impact of LH-C on




LH-C (Lot No. B1502001) was provided by Shijiazhuang
Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, China).
The raw material of LH-C is black powder, comprising
13 ingredients as shown in Table 1. LH-C was dissolved
in DMSO to 500 mg/mL and stored at −20 °C prior to
use. Serum-free medium or saline was used as the
dilution buffer in the follow-up experiments.
Cells and viruses
Influenza virus A/PR/8/34 (H1N1), B/Lee/1940, A/
Guangdong/GIRD02/09 (H1N1), A/Aichi/2/68 (H3N2),
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A/Hongkong/1/68(H3N2), A/Duck/Hongkong/Y280/
97(H9N2), A/Duck/Guangdong/09 (H6N2), and A/Shanghai/
01/2013(H7N9) were propagated in the allantoic cavity of
chicken eggs. An oseltamivir-resistant variant of
H1N1 influenza virus A/PR/8/34 (H1N1) (H274Y mut)
and mouse-adapted influenza virus (A/PR/8/34, H1N1)
was propagated in MDCK cells. The virus titers were
determined based on a 50% tissue culture infectious dose
(TCID50) assay. Madin-Darby canine kidney (MDCK) cells
and A549 cells, a human alveolar type II-like epithelial cell
line, were cultured in a monolayer in Minimum Essential
Medium (MEM) or Dulbecco’s modified Eagle’s medium
(DMEM) respectively, supplemented with 10% fetal
bovine serum (FBS), penicillin (100 U/mL) and strepto-
mycin (10 μg/mL), incubated at 37 °C under 5% CO2. In
vitro experiments were conducted in a biosafety level 2
containment facility. All procedures involving live H7N9
viruses were conducted at a biosafety level 3 facility.
Animals
Specific-pathogen-free BALB/c female mice weighing ap-
proximately 16 to 18 g were purchased from Guangdong
Medical Laboratory Animal Center (Guangzhou, China).
The animals were fed a standard laboratory diet and
provided water ad libitum. The animal experiments
were performed in accordance with the Guidelines of
Guangdong Regulation for the Administration of
Laboratory Animals.
Cytotoxicity assay
MDCK cells were plated onto 96-well plates and cultured
to reach 80–90% confluence at 37 °C under 5% CO2 for
24 h. The aspirated medium contained various concentra-
tions of LH-C (0.625–20 mg/mL, 100 μL/well), and the
cells were further incubated at 37 °C for 48 h. Approxi-
mately 20 μL of Methyl Thiazolyl Tetrazolium (MTT) at
concentration of 5 mg/mL was added to each well, and
the cells were further incubated at 37 °C for 4 h. The
medium was subsequently removed, and formazan
crystals were solubilized with dimethyl sulfoxide (DMSO)
(100 μL/well). The absorbance was measured at 490 nm
using a microplate reader [20]. The 50% toxic concentra-
tion (TC50) was calculated using the Reed-Muench
analysis [21].
Antiviral assay
The anti-influenza virus activity of LH-C was examined
using cytopathogenic effect (CPE) and MTT assays [22].
Briefly, MDCK cells were seeded onto 96-well plates and
infected with 100 TCID50/100 μl of influenza virus at
37 °C for 2 h. The medium was aspirated, and the cells
were incubated with 100 μl of serum-free MEM contain-
ing 1.5 μg/ml of trypsin, antibiotics and various concen-
trations of LH-C (0.03125-2 mg/mL) at 37 °C under 5%
CO2 for 2–3 days. LH-C was dissolved in DMSO and
diluted in culture medium to obtain various final con-
centrations. The concentration of DMSO in each
medium was less than 1%. Approximately 20 μL/well of
MTT (5 mg/ml) was subsequently added into each well,
and the cells were further incubated for 4 h at 37 °C in a
CO2 incubator. The crystallized formazan in the plates
was dissolved in DMSO (100 μL/well). The absorbance
was measured at 490 nm using a computer-controlled
microplate reader (Bio-Rad, Tokyo, Japan) [20].
Plaque reduction assay
MDCK cells (5 × 105 cells/well) were plated onto 12-well
culture plates and incubated for 24 h. The cells were
washed twice with phosphate-buffered saline (PBS) prior
to incubation with viruses (including A/PR/8/34 (H1N1),
A/Hongkong/1/68 (H3N2), oseltamivir-resistant viruses
(H1N1) and A/Guangzhou/GIRD02/09(H1N1) diluted
in serum-free MEM containing 1% penicillin and
streptomycin for 2 h at 37 °C. After incubation, the cell
monolayer was covered with overlay medium containing
LH-C and further cultured at 34 °C under 5% CO2 for
72 h. Subsequently, the overlay medium was removed,
and the cell monolayer was fixed with 10% formalin,
stained with 1% crystal violet, and the plaques were
counted [23].
Time course assay
MDCK cells in 48-well plates were infected with virus
A/PR/8/34 (H1N1) (MOI =0.1) for 2 h. After infection,
the supernatant was removed, and the cells were rinsed
twice with PBS. LH-C (2 mg/mL) was added to cells at
0, 2, 4, 6, 8 and 10 h after infection. The time of addition
studies were conducted under single-cycle virus growth
Table 1 Composition of LH-C
Plant Family Weight Used part
Forsythia suspensa (Thunb.) Vahl Oleaceae 255 g Fructus
Ephedra sinica Stapf Ephedraceae 85 g Stem
Lonicera japonica Thunb. Caprifoliaceae 255 g Flower bud
Isatis indigotica Fortune Brassicaceae 255 Root
Mentha haplocalyx Briq. Mentha 7.5 g Menthol
Dryopteris crassirhizoma Nakai Dryopteridaceae 255 g Rhizoma
Rhodiola rosea L. Crassulaceae 85 g Rhizoma
Gypsum Fibrosum – 255 g –
Pogostemon cablin (Blanco)
Benth.
Labiatae 85 g Whole
plant
Rheum palmatum L. Polygonaceae 51 g Rhizoma
Houttuynia cordata Thunb. Saururaceae 255 g Whole
plant
Glycyrrhiza uralensis Fisch. Leguminosae 85 g Rhizoma
Armeniaca sibirica (L.) Lam. Rosaceae 85 g Seed
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conditions. The supernatant was harvested at 12 h post
infection, and the virus titers were determined in MDCK
cells [24].
Indirect immunofluorescence assay
MDCK cells were seeded onto 48-well plates (200 μL/well);
when the cell culture reached 50% at 37 °C under 5% CO2,
the virus A/PR/8/34(H1N1) (MOI =0.1) was infected for
2 h. After incubation, the supernatant was aspirated, the
cells were washed twice with PBS, and LH-C (2 mg/mL)
was subsequently added to cells, followed by incubation at
37 °C under 5% CO2. At 6 and 8 h post infection, the cells
were fixed with 4% PFA in PBS for 30 min at 4 °C The cells
were permeabilized with 0.5% Triton X-100 in PBS for
15 min at room temperature and blocked with 5% BSA in
PBS for 20 min at 37 °C, adding anti-influenza A
virus NP antibody overnight at 4 °C. After further
washing, the cells were incubated with FITC-labeled
goat anti-mouse IgG at 37 °C for 1 h. The nuclei
were stained with DAPI (5 μg/mL), and fluorescence
was visualized using a Zeiss Axiovert 135 fluorescence
microscope.
RNA extraction, reverse transcription, and real-time quan-
titative PCR (qRT-PCR)
The relative gene expression in A549 cells infected with
A/Puerto Rico/8/34 H1N1 was analyzed using qRT-PCR.
Total RNA was extracted with 1 ml of TRIzolTM reagent
(Invitrogen Life Technologies) and dissolved in RNase-
free water. One microgram from each RNA extract was
used to generate first-strand cDNA using the Prime-
Script RT-PCR Kit (Takara Bio) using both oligo (dT)
and random primers. qRT-PCR was performed using an
ABI7500 system (Applied Biosystems) with the following
conditions: 95 °C for 30 s, followed by 40 cycles of 95 °C
for 5 s and 60 °C for 30 s. Forward and reverse primers
in combination with FAM/TAMRA probes sequences
for IL-6, IL-8, IP-10, TNF-α, MCP-1 and GADPH genes
were previously published and listed in Additional file 1:
Table S1. Relative gene expression levels were calculated
as 2-△△CT (Sym et al., [4]).
Western blotting
A549 cells were inoculated into a culture flask contain-
ing DMEM/F12 (1:1) culture medium (HyClone,
Thermo Scientific Inc.) supplemented with 10% (v/v)
fetal bovine serum (FBS). After growing to over 80%
confluence, the cells were seeded onto 6-well plates at a
density of 2x105 and subsequently infected with influ-
enza A virus (PR8) (MOI = 0.1) in the absence or
presence of different concentrations of LH-C. The cells
were washed twice with cold PBS and subsequently lysed
in commercial RIPA lysis buffer (Beyotime) containing
Complete, Mini, EDTA-free protease inhibitor cocktail
(Roche). Protein concentrations were determined using
the BCA Protein Assay kit (Pierce) according to the
manufacturer’s instructions. The proteins were separated
using SDS-PAGE and subsequently transferred to PVDF
membranes, followed by blocking for an hour at room
temperature in 5% nonfat milk in TBST. Following
incubation with antibodies against phospho Ser536-NF-
kBp65, phospho Thr202/Tyr204-ERK, NF-kB, ERK,
GAPDH (Cell Signaling) and a secondary HRP-
conjugated antibody, the immunocomplexes were
detected using enhanced chemiluminescence (ECL,
Amersham).
Mouse inoculation and anti-viral treatment
The mice were intranasally infected with 2 MLD50 of
mouse-adapted A/PR/8/34 (H1N1) virus in a volume of
50 μL. Groups of mice were orally administered 1300
and 650 mg/kg/day of LH-C solution respectively. The
control animals were treated with the solvent only. The
drug was administered twice a day (at 12-h intervals) for
5 days.
Sample collection, process and detection
One set of 14 mice was monitored for weight loss
from 3 days before to 15 days post infection of the
virus. A second set of animals was sacrificed at 4, 6,
and 8 days after infection and the lung samples were
harvested. Lung tissues from euthanized mice were
extracted and homogenized in MEM containing anti-
biotics (0.1% penicillin-streptomycin). The obtained
specimens were centrifuged at 12,000 rpm for 5 min
at 4 °C, aliquoted and stored at −80 °C for further
analysis. The lung homogenates were determined
according to the virus titer using end-point titration
in MDCK cells and real-time RT-PCR for mRNA
expression as previously described.
Histopathological analysis
The lungs were inflated with 10% formaldehyde
solution. The tissues were processed for paraffin em-
bedding and cut into 4-μm-thick sections. The tissue
samples were subjected to standard hematoxylin and
eosin staining.
Statistical analysis
The data are expressed as the means ± S.E.M. Statistical
differences between two groups were determined using
Student’s t test. For multiple groups, one-way ANOVA
analysis was used to compare the means. Statistical
analyses were conducted using SAS 9.1. P < 0.05 was
considered statistically significant. For survival studies, a
log-rank (Mantel-Cox) test using GraphPad Prism
(GraphPad 5.0 Software) was conducted.
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Results
In vitro anti-influenza activity of LH-C against different
influenza viruses
In a first set of experiments we investigated whether
LH-C exerts antiviral effect against influenza viruses
infection in cultured cells. Therefore the cells were
infected with virus and incubated for 72 h with LH-C at
various concentrations. For infection, we used different
virus strains, including the highly pathogenic avian influenza
(HPAI) H7N9 influenza virus A/Shanghai/01/2013 (H7N9),
swine-origin influenza A virus A/Duck/Guangdong/2009
(H6N2) and/Duck/Guangdong/Y280/92 (H9N2) and the
influenza B virus prototype isolate B/Lee/1940. As shown in
Table 2, LH-C exhibited inhibitory activities against several
influenza viruses from different human isolates and avian
influenza viruses, with IC50 ranging from 0.35 to 2 mg/mL,
and a selective index (SI) ranging from 1.56 to 15.6. LH-C
showed the best inhibitory effect in A/Aichi/2/68(H3N2)
and A/Duck/Guangdong/Y280/92 (H9N2) (SI = 15.85 and
8.80, respectively). Interestingly, LH-C displayed no effect
towards B/Lee/1940. The anti-influenza virus activities of
LH-C against A/GIRD02/09 (H1N1), A/Aichi/2/68 (H3N2)
and A/PR/8/34 (H1N1) (H274Y mut) were examined by
plaque reduction assay (Fig. 1).
LH-C treatments blocked the early stages of viral
replication process
To determine the step in the virus replicate cycle that is
affected by LH-C, supernatants from cells that were
treated with LH-C at different time points pre- and
post-infection were analyzed for their content of progeny
virus (Fig. 2a) and viral gene expression (Fig. 2b). Inter-
estingly, most prominent reductions of virus titers were
obtained in the early stages of viral replication (0–2 h).
In the late stages of viral replication (4–8 h), LH-C
displayed an insignificant effect. It suggested that the
antiviral mechanism of LH-C involves the inhibition of
early-stage influenza virus replication.
LH-C inhibits nuclear export of virus nucleocapsid protein
(RNP) in the infected A549 cells
Earlier findings clearly indicated that the inhibition of
NF-kB pathway resulted in efficient retention of influ-
enza virus RNP complexes in the nucleus of infected
cells without affecting accumulation of viral proteins
[25]. Therefore, we investigated whether LH-C could
block nuclear export of viral RNP in the infected A549
cells. As shown in Fig. 3, Immunofluorescence staining
of the viral NP, which is one of the constituents of the
Table 2 Antiviral activity of LH-C against influenza viruses
Virus type and strain LH-C
IC50 (mg/ml)
a SI
A/PR/8/34 (H1N1) 0.51 6.21
A/Guangzhou/GIRD02/2009 (H1N1) 0.71 4.46
A/Aichi/2/68 (H3N2) 0.2 15.85
B/Lee/1940 2 1.59
A/Duck/Guangdong/2009 (H6N2) 1 3.17
A/Duck/Guangdong/Y280/92 (H9N2) 0.42 8.80
A/Shanghai/01/2013 (H7N9) 0.85 3.68
The concentration required for TC50 of LH-C was 3.17 mg/ml to MDCK cells
based on the MTT assay
aMean of the results from three independent experiments
Fig. 1 Plaque reduction assay of LH-C against influenza viruses. MDCK cells were infected with influenza viruses, including A/GIRD02/09 (H1N1),
A/Aichi/2/68 (H3N2) and A/PR/8/34 (H1N1) (H274Y mut) at 0.01 MOI for 2 h at 34 °C. After viral adsorption, cell monolayer was covered with overlay
medium containing LH-C in different concerntration. After incubation for 72 h, the cells were fixed and stained with crystal violet
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RNP complexes reveals that the export of viral RNP
were efficiently impaired in the presents of LH-C.
LH-C inhibits influenza A virus-induced NF-κB activation
in A549 cells
A variety of cellular signal pathways can be triggered in
response to influenza A virus infection [26, 27]. The ac-
tivation these signal pathways can be manipulated by vi-
ruses for efficient replication or the induction of host
defense mechanisms against invading viruses [28]. Thus,
we examined the effect of LH-C on different signaling
transduction mechanisms after influenza A virus infec-
tion. Viral infection significantly increased the activation
of NF-κB and Raf/MEK/ERK signaling in human alveo-
lar epithelial (A549) cells (Fig. 4, Lane 1, 3). LH-C
treatment suppressed influenza A virus-induced NF-kB
activation but not the Raf/MEK/ERK cascade in virus-
infected cells over a 24-h period (Fig. 4, Lane 3).
LH-C inhibits influenza A virus-induced cytokine/chemo-
kine expression in A549 cells
NF-κB pathway plays as a major regulator of cytokine
and chemokine expression after influenza virus infection
[28]. The overexpression of cytokines and chemokines
induced through influenza virus infection depends on
the NF-κB signaling pathway. A previous study showed
that influenza A/PR/8 virus infection with specific NF-
κB inhibitor treatment decreased the production of
inflammatory cytokines, including IL-8 and IL-6 [29]. To
examine the NF-kB inhibition effect of LH-C on virus-
induced inflammatory responses, we used qRT-PCR to
measure cytokine/chemokine expression in A549 cells
Fig. 2 MDCK cells in 48-well plates were prepared and subsequently infected with virus A/PR/8/34 (H1N1) (MOI =0.01) for 2 h, after that LH-C
(2 mg/mL) was added to the cells at −2, 0, 2, 4, 6 and 8 h after infection. The supernatants were collected and infectious titers were determined
by MTT assay (a) and real time PCR assay (b). The data represent the means ± SD of 3 biological samples. The data are presented as the means ± SEM
of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 3 Indirect immunofluorescence microscopy. A549 cells were
infected with A/PR/8/34 (H1N1) (MOI = 0.1) and treated with LH-C
(2 mg/mL) or vehicle. After 6 and 8 h post infection, the cells were
fixed for 30 min at 4 °C. Cell nuclei were stained with DAPI (blue)
and viewed using a fluorescence microscope (Magnification 400×)
Fig. 4 Effect of LH-C on influenza virus-induced signaling expression
in A549 cells. A549 cells infected with A/PR/8/34(H1N1) (MOI = 0.1)
were treated with 1.5–3 mg/ml LH-C for 24 h. Whole-cell lysates were
prepared at the indicated time points, and an immunoblot analysis of
the activity of NF-κB and MAPKs ERK1/2 was performed using
phospho-specific and total expression antibodies
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infected with PR8 (MOI = 0.1) at 24 h p.i. As shown in
Fig. 5, virus infection induced a robust increase in the
gene expression of IL-6, IL-8, TNF-α, IP-10, MCP-1,
whereas LH-C treatment exhibited a prominent inhibi-
tory effect in a dose-dependent manner.
Administration of LH-C exhibits antiviral functions in vivo
To confirm the viral inhibitor properties of LH-C,
groups of mice are inoculated with A/PR/8 (H1N1) virus
in 2 MLD50 and subsequently administered LH-C and
placebo, respectively. At 2, 4, 6 and 8 days post infection;
the lungs were then collected from infected mice (3 mice
per day) for the detection of the virus titer. As is shown
in Fig. 6, A decrease (>2 log) of the viral titers in the
lungs of mice by TCID50 was observed in groups admin-
istered LH-C (1300 mg/kg/day) compared with placebo
at 6 and 8 days post challenge. Low-dosage LH-C treat-
ment groups also presented reduced lung viral titers,
although these values were not significantly different
from those of the control group. These results suggested
that LH-C has potential antiviral activity against influ-
enza A viruses in mice.
Administration of LH-C reduced the inflammatory
response in the lungs of mice after influenza A virus
infection
To determine the properties of LH-C in modulating
cytokine production during influenza virus infection, we
examined the level of cytokines in the lungs of infected
mice at 4, 6 and 8 days post infection. As shown in Fig. 7,
the expression of pro-inflammatory cytokines (TNF-α
and IL-6) and chemokines (KC and MCP-1) was strongly
reduced in the presence of LH-C from 4 to 6 days post
infection. The levels of IL-1β and IP-10 were also sup-
pressed in a dose-dependent manner.
Administration of LH-C reduced lung pathology induced
by influenza infection
Lung histology was examined to determine whether LH-
C treatment alleviated lung pathology resulting from in-
fluenza infection. As shown in Fig. 8, using hematoxylin
and eosin (HE) staining, the lung tissues of infected ani-
mals showed considerable inflammation, with cell exu-
dates in the lung parenchyma and small airways.
Following LH-C treatment, the significant eradication of
perivascular inflammation and fewer cell exudates were
observed. Considering previous results showing viral
loads following LH-C administration, these results sug-
gested that LH-C treatment improved the lung path-
ology of influenza-infected mice.
Discussion
LH-C has been widely used for more than 10 years in
China. Previous studies have confirmed the curative ef-
fects of LH-C on several diseases, such as acute bron-
chitis, asthma, and COPD. A randomized controlled
Fig. 5 Effect of LH-C on influenza virus-induced cytokine/chemokine mRNA expression in A549 cells. A549 cells infected with A/PR/8/34(H1N1)
(MOI = 0.1) were treated with 1.5–3 mg/ml LH-C for 24 h prior to extracting RAN. The cytokine/chemokine mRNA level of IL-6, IL-8, IP-10, TNF-α, and
MCP-1 was analyzed using qRT-PCR. The data are presented as the means ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001
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trial for the comparison of LH-C with oseltamivir in
therapeutic effects on mild H1N1 infection demon-
strated that LH-C has a comparative effect in viral clear-
ance and performs even better in symptom relief [18].
However, the mechanism of LH-C action remains un-
clear. In this study, demonstrated that LH-C could in-
hibit different strains of influenza viruses, including
HPAI A (H7N9) virus, the newly emerged A (H1N1)
pdm09 virus and oseltamivir-resistant viruses (A/PR/8
H274Y). Treatment with LH-C following infection had
an inhibitory effect on plaque reduction of the human or
avian influenza viruses tested. Additionally, LH-C inhib-
ited viral replication when added between 0 and 6 h, and
particularly 0–2 h, after infection.
Similar to all other viral pathogens, influenza virus
utilizes the host cellular machinery to support replication.
NF-kB pathway plays an important role in the mainten-
ance of host defense responses [30], independent studies
have demonstrated that the pathway is critical for the effi-
cient replication of influenza virus. The results of our
experiments that LH-C could suppress A/PR/8/34 virus-
induced phosphorylation of p65 in cells. Previous reports
have demonstrated that viruses support NF-kB-dependent
expression of proapoptotic factor, FasL and TRAIL, which
activates caspases that subsequently regulate the nuclear
export of the viral RNP complexes. Here, we demon-
strated that LH-C could block the nuclear export of the
viral RNP regardless of the virus-induced activation of
Raf/MEK/ERK pathway, indicating that the antiviral effect
of LH-C was predominantly via its NF-kB inhibiting activ-
ity to suppress viral RNP export and subsequent viral
propagation. The NF-kB signaling pathway is not only
involved in viral replication but is also the main regulator
of cytokine and chemokine production in general and
particularly during severe influenza infections [31–33].
We also demonstrated that the levels of cytokine/
Fig. 6 Administration of LH-C efficiently reduced influenza A virus replication in vivo. Three BALB/c mice per group were intranasally infected with
2 MLD50 of A/PR/8/34 (H1N1) virus. The mice were orally administered LH-C (650 or 1300 mg/day). a Mice were monitored for changes in body
weight daily. b Influenza virus titers were detected in mice lungs at 2, 4, 6 and 8 days post inoculation. The data are presented as the means ± SEM of
3 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 7 Inflammatory cytokines and chemokines were detected at the indicated days post infection. The cytokine/chemokine mRNA level was
analyzed using qRT-PCR. The data are presented as the means ± SD.*P < 0.5, **P < 0.01, ***P < 0.001
Fig. 8 lung histology was examined at 4 and 6 days post inoculation. Sections of the lung tissues were visualized using hematoxylin and eosin
(H&E) staining. (Magnification: 100×)
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chemokine mRNA (including IL-6, 8, MCP-1 MIG, and
IP-10) in infected cells were reduced in the presence of
LH-C, indicating the regulatory activity of LH-C in an
NF-kB-dependent manner. Blocking the NF-kB pathway
as a potent strategy in influenza treatment has recently
been considered, as this strategy will not only block virus
propagation but also inhibit the development of related
inflammation [25–29]. Previous studies have reported
that NF-kB inhibitors show a considerable protective
effect in mice against HPAI A virus infection [30],
indicating the availability of NF-kB inhibitors for the
treatment of HPAI virus.
Inflammatory cytokines and chemokines are produced
during influenza virus infection. However, the multiple
functions of cytokines could either be beneficial or detri-
mental to virus-infected hosts. To assess whether the
antiviral and anti-inflammation properties of LH-C
observed in cell culture would also be relevant in vivo
compared with the placebo group, a notable pattern of
regulation with cytokine was observed in LH-C-treated
mice, particularly in NF-kB-dependent cytokines. We
observed that the production of pro-inflammation
TNF-α and IL-6 and the immunoregulatory IFN-β,
MCP-1 and KC were significantly decreased later in in-
fection (at 6 or 8 dpi) compared with non-treated mice,
indicating the accelerated recovery from the immunity
situation resulting from infection.
The adoptive concentrations (650 and 1300 mg/d)
used in the in vivo study were based on the practical
concentrations used in humans, though these concentra-
tions were higher than conventional medicines, the
results still showed no toxic side effects in mice, which
is still in the range of the safety dose. In conclusion,
LH-C might be a promising option as a new antiviral
agent to fight IAV infections.
Conclusions
LH-C, as a TCM prescription, has shown a broad
spectrum of effects on a series of influenza viruses,
including the newly emerged H7N9. LH-C exerts its
anti-influenza activity by interfering with both viral and
host reactions. Specifically, LH-C regulates the immune
response of virus infection. Thus, LH-C might be a
promising option in treating Influenza disease.
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